Categories AlphaGraphs, Earnings, Technology
Cisco (CSCO) reports Q4 results: Here’s all you need to know
Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced results for the fourth quarter of 2023, reporting higher revenues and earnings. The company also provided guidance for the first quarter of 2024.
The San Jose-headquartered network gear maker said that earnings, excluding special items, rose to $1.14 per share in the July quarter from $0.83 per share in the same period of 2022. Unadjusted net income was $4.0 billion or $0.97 per share, compared to last year’s profit of $2.8 billion or $0.68 per share.
At $15.2 billion, fourth-quarter revenues were up 16% year-over-year. The top line benefitted from strong contributions from the core Secure, Agile Networks division.
“We are seeing solid customer demand, gaining market share, and innovating in key areas like AI, security, and cloud. This momentum gives us confidence in our ability to capture the many opportunities ahead,” said Cisco’s CEO Chuck Robbins.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
